Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) shares saw unusually-strong trading volume on Monday after Oppenheimer raised their price target on the stock from $54.00 to $70.00. Oppenheimer currently has an outperform rating on the stock. Approximately 670,122 shares changed hands during mid-day trading, an increase of 28% from the previous session’s volume of 524,894 shares.The stock last traded at $59.34 and had previously closed at $58.24.

Several other equities research analysts have also recently commented on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, February 8th. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Tuesday, January 15th. ValuEngine raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target (up from $48.00) on shares of Biohaven Pharmaceutical in a research report on Monday, March 4th. Finally, Barclays reissued a “hold” rating and set a $52.00 price target on shares of Biohaven Pharmaceutical in a research report on Tuesday, March 19th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $62.57.

In other news, Director Declan Doogan sold 40,000 shares of the company’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $44.31, for a total value of $1,772,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Vlad Coric sold 100,000 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $50.09, for a total transaction of $5,009,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 310,206 shares of company stock worth $14,996,874. 34.20% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the company. Stifel Financial Corp raised its holdings in Biohaven Pharmaceutical by 555.2% in the 4th quarter. Stifel Financial Corp now owns 2,719,538 shares of the company’s stock valued at $100,569,000 after acquiring an additional 2,304,438 shares during the period. BlackRock Inc. raised its holdings in Biohaven Pharmaceutical by 10.4% in the 4th quarter. BlackRock Inc. now owns 2,393,148 shares of the company’s stock valued at $88,499,000 after acquiring an additional 225,386 shares during the period. JPMorgan Chase & Co. raised its holdings in Biohaven Pharmaceutical by 7.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,532,361 shares of the company’s stock valued at $57,540,000 after acquiring an additional 105,913 shares during the period. Samlyn Capital LLC raised its holdings in Biohaven Pharmaceutical by 32.8% in the 4th quarter. Samlyn Capital LLC now owns 921,536 shares of the company’s stock valued at $34,078,000 after acquiring an additional 227,432 shares during the period. Finally, Foresite Capital Management IV LLC raised its holdings in Biohaven Pharmaceutical by 0.6% in the 4th quarter. Foresite Capital Management IV LLC now owns 855,900 shares of the company’s stock valued at $31,651,000 after acquiring an additional 4,700 shares during the period. 88.91% of the stock is currently owned by institutional investors.

The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -9.74 and a beta of 0.50.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings results on Thursday, February 28th. The company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.06). On average, research analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -6.16 EPS for the current fiscal year.

WARNING: “Biohaven Pharmaceutical (BHVN) Sees Unusually-High Trading Volume on Analyst Upgrade” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2019/04/16/biohaven-pharmaceutical-bhvn-sees-unusually-high-trading-volume-on-analyst-upgrade.html.

Biohaven Pharmaceutical Company Profile (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: How can you know how many shares are floating?

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.